JPWO2021113820A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021113820A5 JPWO2021113820A5 JP2022532614A JP2022532614A JPWO2021113820A5 JP WO2021113820 A5 JPWO2021113820 A5 JP WO2021113820A5 JP 2022532614 A JP2022532614 A JP 2022532614A JP 2022532614 A JP2022532614 A JP 2022532614A JP WO2021113820 A5 JPWO2021113820 A5 JP WO2021113820A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- compound according
- group
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 32
- 108020004459 Small interfering RNA Proteins 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 14
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims description 12
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims description 12
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 12
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 150000001720 carbohydrates Chemical class 0.000 claims description 8
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
- 125000001475 halogen functional group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000005647 linker group Chemical group 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 150000002016 disaccharides Chemical class 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 102100037429 17-beta-hydroxysteroid dehydrogenase 13 Human genes 0.000 description 3
- 101000806241 Homo sapiens 17-beta-hydroxysteroid dehydrogenase 13 Proteins 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101150032427 Arf1 gene Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
Description
結果
図4は、本発明の特定のsiRNAコンジュゲートのカニクイザルにおけるインビボ活性を示す。GalNAc-siRNAコンジュゲートの単回投与をオスのカニクイザルに皮下注射した。注射後14日目に、それぞれの動物の肝臓を収集し、肝臓のHSD17B13のmRNAレベルをRT-qPCRで決定し、3つの内因性対照mRNAレベル(GAPDH、Arf1、Eif1)の平均に正規化した。HSD17B13/内因性対照の比は、生理食塩水で処理された対照動物のものに対してさらに正規化された。示されているように、投与後14日で、siRNAコンジュゲートの一例はHSD17B13のmRNAレベルを有意に低下させ、3mg/kgの用量レベルで70%低下した。
最後に、本発明の好ましい実施態様を項分け記載する。
[実施態様1]
式(I)
R
1
は標的化リガンドであり;
L
1
は存在しないか、連結基であり;
L
2
は存在しないか、連結基であり;
R
2
は、siRNA1~siRNA119のうちのいずれか1つから選択されるsiRNA分子であり;
環Aは、存在しないか、3~20員のシクロアルキル、5~20員のアリール、5~20員のヘテロアリール、もしくは3~20員のヘテロシクロアルキルであり;
それぞれのR
A
は、水素、ヒドロキシ、CN、F、Cl、Br、I、-C
1-2
アルキル-OR
B
、C
1-10
アルキルC
2-10
アルケニル、及びC
2-10
アルキニルからなる群から独立して選択され;C
1-10
アルキルC
2-10
アルケニル、及びC
2-10
アルキニルは、ハロ、ヒドロキシ、及びC
1-3
アルコキシから独立して選択される1つ以上の基で任意選択で置換されており;
R
B
は水素もしくは保護基であり;
nは、0、1、2、3、4、5、6、7、8、9、もしくは10である〕
の化合物またはその塩。
[実施態様2]
R
1
が-C(H)
(3-p)
(L
3
-サッカリド)
p
であり、
式中、
それぞれのL
3
が、独立して連結基であり;
pが、1、2、もしくは3であり;
サッカリドが単糖もしくは二糖であるか、
またはその塩である、実施態様1に記載の化合物。
[実施態様3]
前記サッカリドが、
XがNR
3
であり、Yが、-(C=O)R
4
、-SO
2
R
5
、及び-(C=O)NR
6
R
7
から選択されるか;もしくはXが-(C=O)-であり、YがNR
8
R
9
であり;
R
3
が水素または(C
1
-C
4
)アルキルであり;
R
4
、R
5
、R
6
、R
7
、R
8
、及びR
9
がそれぞれ、水素、(C
1
-C
8
)アルキル、(C
1
-C
8
)ハロアルキル、(C
1
-C
8
)アルコキシ、ならびにハロ、(C
1
-C
4
)アルキル、(C
1
-C
4
)ハロアルキル、(C
1
-C
4
)アルコキシ、及び(C
1
-C
4
)ハロアルコキシからなる群から独立して選択される1つ以上の基で任意選択で置換された(C
3
-C
6
)シクロアルキルからなる群から独立して選択され、
R
10
が-OH、-NR
8
R
9
、もしくは-Fであり;
R
11
が、-OH、-NR
8
R
9
、-F、もしくは、ハロ、ヒドロキシル、カルボキシル、アミノ、(C
1
-C
4
)アルキル、(C
1
-C
4
)ハロアルキル、(C
1
-C
4
)アルコキシ、及び(C
1
-C
4
)ハロアルコキシからなる群から独立して選択される1つ以上の基で任意選択で置換された5員複素環である〕
またはその塩である、実施態様2に記載の化合物。
[実施態様4]
前記サッカリドが、
[実施態様5]
前記サッカリドが、
[実施態様6]
前記式Iの化合物が、
[実施態様7]
前記式(I)の化合物が、
[実施態様8]
前記siRNAの配列が化学的に修飾されたヌクレオチドを含む、実施態様1~7のいずれかに記載の化合物。
[実施態様9]
前記siRNAが、少なくとも1つの2’Ome修飾または2’F修飾を含む、実施態様8に記載の化合物。
[実施態様10]
前記siRNAが、少なくとも1つの2’Ome修飾及び少なくとも1つの2’F修飾を含む、実施態様9に記載の化合物。
[実施態様11]
前記siRNAが、少なくとも1つの2’Ome修飾及び少なくとも1つの2’F修飾を含む、実施態様9に記載の化合物。
[実施態様12]
肝線維症を治療する方法であって、実施態様1~11のいずれかに記載の化合物の有効量を、それを必要とする患者に投与することを含む、前記方法。
[実施態様13]
非アルコール性脂肪性肝炎(NASH)を治療する方法であって、実施態様1~11のいずれかに記載の化合物の有効量を、それを必要とする患者に投与することを含む、前記方法。
[実施態様14]
非アルコール性脂肪性肝炎(NASH)と関連する肝線維症を治療する方法であって、実施態様1~11のいずれかに記載の化合物の有効量を、それを必要とする患者に投与することを含む、前記方法。
[実施態様15]
アルコール性脂肪性肝炎(ASH)を治療する方法であって、実施態様1~11のいずれかに記載の化合物の有効量を、それを必要とする患者に投与することを含む、前記方法。
[実施態様16]
アルコール性脂肪性肝炎(ASH)と関連する肝線維症を治療する方法であって、実施態様1~11のいずれかに記載の化合物の有効量を、それを必要とする患者に投与することを含む、前記方法。
[実施態様17]
肝線維症を治療するための、実施態様1~11のいずれかに記載の化合物の有効量の使用。
[実施態様18]
非アルコール性脂肪性肝炎(NASH)またはアルコール性脂肪性肝炎(ASH)を治療するための、実施態様1~11のいずれかに記載の化合物の有効量の使用。
[実施態様19]
非アルコール性脂肪性肝炎(NASH)またはアルコール性脂肪性肝炎(ASH)と関連する肝線維症を治療するための、実施態様1~11のいずれかに記載の化合物の有効量の使用。
[実施態様20]
前記式(I)の化合物が皮下投与される、実施態様12~19のいずれかに記載の方法または使用。
[実施態様21]
siRNA1-siRNA119からなる群から選択される二本鎖siRNA分子。
[実施態様22]
実施態様21に記載の二本鎖siRNA分子を含む組成物。
[実施態様23]
本明細書に記載の発明。
Results Figure 4 shows the in vivo activity of certain siRNA conjugates of the invention in cynomolgus monkeys. A single dose of GalNAc-siRNA conjugate was injected subcutaneously into male cynomolgus monkeys. On day 14 post-injection, the liver of each animal was collected and hepatic HSD17B13 mRNA levels were determined by RT-qPCR and normalized to the average of three endogenous control mRNA levels (GAPDH, Arf1, Eif1). . The HSD17B13/endogenous control ratio was further normalized to that of saline-treated control animals. As shown, 14 days after administration, one example of the siRNA conjugate significantly reduced HSD17B13 mRNA levels, by 70% at the 3 mg/kg dose level.
Finally, preferred embodiments of the present invention will be described in sections.
[Embodiment 1]
Formula (I)
R 1 is a targeting ligand;
L 1 is absent or is a linking group;
L 2 is absent or is a linking group;
R 2 is an siRNA molecule selected from any one of siRNA1 to siRNA119;
Ring A is absent or is a 3 to 20 membered cycloalkyl, a 5 to 20 membered aryl, a 5 to 20 membered heteroaryl, or a 3 to 20 membered heterocycloalkyl;
Each R A is a group consisting of hydrogen, hydroxy, CN, F, Cl, Br, I, -C 1-2 alkyl-OR B , C 1-10 alkylC 2-10 alkenyl, and C 2-10 alkynyl C 1-10 alkyl, C 2-10 alkenyl, and C 2-10 alkynyl are optionally selected from one or more groups independently selected from halo, hydroxy, and C 1-3 alkoxy. Replaced with selection;
R B is hydrogen or a protecting group;
n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10]
compound or its salt.
[Embodiment 2]
R 1 is -C(H) (3-p) (L 3 -saccharide) p ,
During the ceremony,
each L 3 is independently a linking group;
p is 1, 2, or 3;
whether the saccharide is a monosaccharide or a disaccharide;
or a salt thereof, the compound according to embodiment 1.
[Embodiment 3]
The saccharide is
X is NR 3 and Y is selected from -(C=O)R 4 , -SO 2 R 5 , and -(C=O)NR 6 R 7 ; or )-, and Y is NR 8 R 9 ;
R 3 is hydrogen or (C 1 -C 4 )alkyl;
R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are each hydrogen, (C 1 -C 8 )alkyl, (C 1 -C 8 )haloalkyl, (C 1 -C 8 )alkoxy, and halo, (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 1 -C 4 )alkoxy, and (C 1 -C 4 )haloalkoxy. independently selected from the group consisting of (C 3 -C 6 )cycloalkyl optionally substituted with one or more groups;
R 10 is -OH, -NR 8 R 9 or -F;
R 11 is -OH, -NR 8 R 9 , -F, or halo, hydroxyl, carboxyl, amino, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, and (C 1 -C 4 ) haloalkoxy, optionally substituted with one or more groups independently selected from the group consisting of
or a salt thereof, the compound according to embodiment 2.
[Embodiment 4]
The saccharide is
[Embodiment 5]
The saccharide is
[Embodiment 6]
The compound of formula I is
[Embodiment 7]
The compound of formula (I) is
[Embodiment 8]
A compound according to any of embodiments 1 to 7, wherein the siRNA sequence comprises chemically modified nucleotides.
[Embodiment 9]
9. A compound according to embodiment 8, wherein the siRNA comprises at least one 2'Ome or 2'F modification.
[Embodiment 10]
10. A compound according to embodiment 9, wherein the siRNA comprises at least one 2'Ome modification and at least one 2'F modification.
[Embodiment 11]
10. A compound according to embodiment 9, wherein the siRNA comprises at least one 2'Ome modification and at least one 2'F modification.
[Embodiment 12]
A method of treating liver fibrosis, said method comprising administering an effective amount of a compound according to any of embodiments 1 to 11 to a patient in need thereof.
[Embodiment 13]
A method of treating non-alcoholic steatohepatitis (NASH), said method comprising administering an effective amount of a compound according to any of embodiments 1 to 11 to a patient in need thereof.
[Embodiment 14]
A method of treating liver fibrosis associated with non-alcoholic steatohepatitis (NASH), comprising administering an effective amount of a compound according to any of embodiments 1 to 11 to a patient in need thereof. The method described above.
[Embodiment 15]
A method of treating alcoholic steatohepatitis (ASH), said method comprising administering an effective amount of a compound according to any of embodiments 1 to 11 to a patient in need thereof.
[Embodiment 16]
A method of treating liver fibrosis associated with alcoholic steatohepatitis (ASH), comprising administering an effective amount of a compound according to any of embodiments 1 to 11 to a patient in need thereof. The method, comprising:
[Embodiment 17]
Use of an effective amount of a compound according to any of embodiments 1 to 11 for treating liver fibrosis.
[Embodiment 18]
Use of an effective amount of a compound according to any of embodiments 1 to 11 to treat non-alcoholic steatohepatitis (NASH) or alcoholic steatohepatitis (ASH).
[Embodiment 19]
Use of an effective amount of a compound according to any of embodiments 1 to 11 for treating liver fibrosis associated with non-alcoholic steatohepatitis (NASH) or alcoholic steatohepatitis (ASH).
[Embodiment 20]
A method or use according to any of embodiments 12 to 19, wherein said compound of formula (I) is administered subcutaneously.
[Embodiment 21]
A double-stranded siRNA molecule selected from the group consisting of siRNA1-siRNA119.
[Embodiment 22]
A composition comprising a double-stranded siRNA molecule according to embodiment 21.
[Embodiment 23]
The invention described herein.
Claims (16)
R1は標的化リガンドであり;
L1は存在しないか、連結基であり;
L2は存在しないか、連結基であり;
R2は、siRNA1~siRNA119のうちのいずれか1つから選択されるsiRNA分子であり;
環Aは、存在しないか、3~20員のシクロアルキル、5~20員のアリール、5~20員のヘテロアリール、もしくは3~20員のヘテロシクロアルキルであり;
それぞれのRAは、水素、ヒドロキシ、CN、F、Cl、Br、I、-C1-2アルキル-ORB、C1-10アルキルC2-10アルケニル、及びC2-10アルキニルからなる群から独立して選択され;C1-10アルキルC2-10アルケニル、及びC2-10アルキニルは、ハロ、ヒドロキシ、及びC1-3アルコキシから独立して選択される1つ以上の基で任意選択で置換されており;
RBは水素もしくは保護基であり;
nは、0、1、2、3、4、5、6、7、8、9、もしくは10である]。
の化合物またはその塩。 Formula (I)
R 1 is a targeting ligand;
L 1 is absent or is a linking group;
L 2 is absent or is a linking group;
R 2 is an siRNA molecule selected from any one of siRNA1 to siRNA119;
Ring A is absent or is a 3 to 20 membered cycloalkyl, a 5 to 20 membered aryl, a 5 to 20 membered heteroaryl, or a 3 to 20 membered heterocycloalkyl;
Each R A is a group consisting of hydrogen, hydroxy, CN, F, Cl, Br, I, -C 1-2 alkyl-OR B , C 1-10 alkylC 2-10 alkenyl, and C 2-10 alkynyl C 1-10 alkyl, C 2-10 alkenyl, and C 2-10 alkynyl are optionally selected from one or more groups independently selected from halo, hydroxy, and C 1-3 alkoxy. Replaced with selection;
R B is hydrogen or a protecting group;
n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10].
compound or its salt.
式中、
それぞれのL3が、独立して連結基であり;
pが、1、2、もしくは3であり;
サッカリドが単糖もしくは二糖であるか、
またはその塩である、請求項1に記載の化合物。 R 1 is -C(H) (3-p) (L 3 -saccharide) p ,
During the ceremony,
each L 3 is independently a linking group;
p is 1, 2, or 3;
whether the saccharide is a monosaccharide or a disaccharide;
2. The compound according to claim 1, which is a salt thereof.
XがNR3であり、Yが、-(C=O)R4、-SO2R5、及び-(C=O)NR6R7から選択されるか;もしくはXが-(C=O)-であり、YがNR8R9であり;
R3が水素または(C1-C4)アルキルであり;
R4、R5、R6、R7、R8、及びR9がそれぞれ、水素、(C1-C8)アルキル、(C1-C8)ハロアルキル、(C1-C8)アルコキシ、ならびにハロ、(C1-C4)アルキル、(C1-C4)ハロアルキル、(C1-C4)アルコキシ、及び(C1-C4)ハロアルコキシからなる群から独立して選択される1つ以上の基で任意選択で置換された(C3-C6)シクロアルキルからなる群から独立して選択され、
R10が-OH、-NR8R9、もしくは-Fであり;
R11が、-OH、-NR8R9、-F、もしくは、ハロ、ヒドロキシル、カルボキシル、アミノ、(C1-C4)アルキル、(C1-C4)ハロアルキル、(C1-C4)アルコキシ、及び(C1-C4)ハロアルコキシからなる群から独立して選択される1つ以上の基で任意選択で置換された5員複素環である]
またはその塩である、請求項2に記載の化合物。 The saccharide is
X is NR 3 and Y is selected from -(C=O)R 4 , -SO 2 R 5 , and -(C=O)NR 6 R 7 ; or )-, and Y is NR 8 R 9 ;
R 3 is hydrogen or (C 1 -C 4 )alkyl;
R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are each hydrogen, (C 1 -C 8 )alkyl, (C 1 -C 8 )haloalkyl, (C 1 -C 8 )alkoxy, and halo, (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 1 -C 4 )alkoxy, and (C 1 -C 4 )haloalkoxy. independently selected from the group consisting of (C 3 -C 6 )cycloalkyl optionally substituted with one or more groups;
R 10 is -OH, -NR 8 R 9 or -F;
R 11 is -OH, -NR 8 R 9 , -F, or halo, hydroxyl, carboxyl, amino, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, and (C 1 -C 4 ) haloalkoxy, optionally substituted with one or more groups independently selected from the group consisting of
3. The compound according to claim 2, which is a salt thereof.
A composition comprising a double-stranded siRNA molecule according to claim 15 .
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962944963P | 2019-12-06 | 2019-12-06 | |
US62/944,963 | 2019-12-06 | ||
PCT/US2020/063617 WO2021113820A1 (en) | 2019-12-06 | 2020-12-07 | Conjugates and methods for treating liver fibrosis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023505434A JP2023505434A (en) | 2023-02-09 |
JPWO2021113820A5 true JPWO2021113820A5 (en) | 2023-12-13 |
Family
ID=76222671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022532614A Pending JP2023505434A (en) | 2019-12-06 | 2020-12-07 | Conjugates and methods for treating liver fibrosis |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220387600A1 (en) |
EP (1) | EP4069276A1 (en) |
JP (1) | JP2023505434A (en) |
KR (1) | KR20220112788A (en) |
CN (1) | CN115884984A (en) |
AU (1) | AU2020398708A1 (en) |
BR (1) | BR112022010613A2 (en) |
CA (1) | CA3163911A1 (en) |
IL (1) | IL293560A (en) |
MX (1) | MX2022006846A (en) |
WO (1) | WO2021113820A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA45478A (en) * | 2016-04-11 | 2019-02-20 | Arbutus Biopharma Corp | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS |
WO2023039076A1 (en) * | 2021-09-08 | 2023-03-16 | Aligos Therapeutics, Inc. | Modified short interfering nucleic acid (sina) molecules and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019012280A (en) * | 2017-04-11 | 2020-01-23 | Arbutus Biopharma Corp | Targeted compositions. |
WO2019051257A2 (en) * | 2017-09-11 | 2019-03-14 | Arbutus Biopharma Corporation | Methods for treating hepatitis b infections |
CA3118142A1 (en) * | 2018-11-02 | 2020-05-07 | Genevant Sciences Gmbh | Therapeutic methods |
-
2020
- 2020-12-07 BR BR112022010613A patent/BR112022010613A2/en unknown
- 2020-12-07 JP JP2022532614A patent/JP2023505434A/en active Pending
- 2020-12-07 CN CN202080091946.7A patent/CN115884984A/en active Pending
- 2020-12-07 KR KR1020227020501A patent/KR20220112788A/en unknown
- 2020-12-07 CA CA3163911A patent/CA3163911A1/en active Pending
- 2020-12-07 IL IL293560A patent/IL293560A/en unknown
- 2020-12-07 AU AU2020398708A patent/AU2020398708A1/en active Pending
- 2020-12-07 MX MX2022006846A patent/MX2022006846A/en unknown
- 2020-12-07 US US17/782,901 patent/US20220387600A1/en active Pending
- 2020-12-07 WO PCT/US2020/063617 patent/WO2021113820A1/en unknown
- 2020-12-07 EP EP20896461.9A patent/EP4069276A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210252021A1 (en) | Formulations of deoxycholic acid and salts thereof | |
AU2018202807B2 (en) | Formulations of deoxycholic acid and salts thereof | |
JP2011511004A5 (en) | ||
JP6752151B2 (en) | UNA oligomer with reduced OFF-TARGET effect in gene silencing | |
KR20180124123A (en) | Medicament obtained by combination of FXR agonist and ARB | |
IL234769A (en) | Parenteral formulations for administering macrolide antibiotics | |
US20100222376A1 (en) | Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders | |
JP2023081922A (en) | Treating and preventing kidney damage | |
EP3305298B1 (en) | Formulations of deoxycholic acid and salts thereof | |
JPWO2019183164A5 (en) | ||
JPWO2021113820A5 (en) | ||
KR20190117318A (en) | Injection composition containing deoxycholic acid having excellent stability and method for preparing the same | |
KR20090089885A (en) | Therapeutic agent for interstitial pneumonia | |
Kohlert et al. | Inhibition of aggression by progesterone and its metabolites in female Syrian hamsters | |
WO2007077893A1 (en) | Therapeutic agent for liver disease and hepatic function-ameliorating agent | |
JPWO2021081420A5 (en) | ||
WO2022102641A1 (en) | Mir-29a-like nucleic acid reagent, liver fibrosis inhibitor, and pharmaceutical composition | |
US20040068006A1 (en) | Method for preventing acute renal failure | |
JP2018039815A (en) | Formulations of deoxycholic acid and salts thereof | |
EA034320B1 (en) | Compositions of sodium deoxycholate |